Product Name | Doramapimod |
Description |
p38 MAP kinase inhibitor |
Purity | >99% (HPLC) |
CAS No. | 285983-48-4 |
Molecular Formula | C31H37N5O3 |
Molecular Weight | 527.7 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO |
Source | Synthetic |
Appearance | White solid |
SMILES | C2=CC(=C1C=CC=CC1=C2NC(NC3=CC(=N[N]3C4=CC=C(C=C4)C)C(C)(C)C)=O)OCCN5CCOCC5 |
InChI | InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37) |
InChIKey | MVCOAUNKQVWQHZ-UHFFFAOYSA-N |
Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
Cite This Product | Doramapimod (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-442) |
Alternative Names | JNK Inhibitor XVII, BIRB796, 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 156422 |
Scientific Background | Doramapimod is a highly potent and selective inhibitor of p38α mitogen-activated protein kinase (MAPK), a key regulator of inflammatory signaling. In neurodegenerative disease research, p38α MAPK is implicated in microglial activation, cytokine production, and neuronal stress responses. Doramapimod is used to explore the therapeutic potential of p38α inhibition in reducing neuroinflammation and protecting against neuronal damage in conditions such as Alzheimer’s disease, ALS, and multiple sclerosis. |
References | 1. Pargellis C., et al. (2002). Nat Structural Biol. 9(4): 268–272. |
Reviews
There are no reviews yet.